bispecific anti-CD19/anti-BCMA CAR T-cell therapy (Shanghai Hrain Biotechnology)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namebispecific anti-CD19/anti-BCMA CAR T-cell therapy (Shanghai Hrain Biotechnology)
Drug Alias Namedual anti-CD19/anti-BCMA CAR T-cell therapy (Shanghai Hrain Biotechnology)HRAIN-002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsTumor necrosis factor ligand superfamily member 13 modulators
TargetsB-lymphocyte antigen CD19Tumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesHrain Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHrain Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A